Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate

Core Points - The World Health Organization (WHO) has declared the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC), marking the second such declaration in two years [1][2] - Tonix Pharmaceuticals has received a grant from the Medical CBRN Defense Consortium (MCDC) to support the development of TNX-801, a vaccine for mpox and smallpox [1][2] - TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox, requiring only a single dose for long-term protection and showing better tolerability compared to traditional vaccines [2][3] Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on pain management therapies and vaccines for public health challenges [3] - The company is advancing TNX-102 SL for fibromyalgia management, with a PDUFA goal date of August 15, 2025, for marketing authorization [3] - Tonix's portfolio includes various candidates targeting CNS disorders, immunology, and infectious diseases, including TNX-801 for mpox and smallpox [3] Market Potential - TNX-801 addresses a significant global unmet need for mpox prevention and control, positioning the company to potentially impact public health positively [2][3] - The MCDC grant will facilitate comprehensive market analyses and commercialization planning for TNX-801 in both private and government markets [1][2]